Shots:
- Novo Nordisk has reported the P-III (STEP Young) trial data assessing semaglutide (1.7 or 2.4mg based on weight at start of trial; QW, SC) vs PBO in 165 children (6 to <12yrs.) with obesity, both in combination with a reduced-calorie diet & increased physical activity
- Trial met its 1EP of superior BMI reduction at Wk. 68, with results showing 40.4% of treated patients no longer classified as having obesity vs 0% with PBO (based on the trial product estimand)
- STEP Young was conducted to meet regulatory post-marketing requirements for semaglutide’s P-III program, with detailed results to be presented at ObesityWeek 2026
Ref: Globenewswire | Image: Novo Nordisk | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
